Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | UBE2M | P61081 | 1/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3028682 | 0.83 | MCHR1 (0.49) | ALDH1A1KDM4ETDP1HTTTACR1 | |
| SCHEMBL3028685 | 0.83 | MCHR1 (0.49) | ALDH1A1KDM4ETDP1HTTTACR1 | |
| SCHEMBL3030479 | 0.83 | MCHR1 (0.49) | ALDH1A1KDM4ETDP1HTTTACR1 | |
| SCHEMBL3038625 | 0.82 | ALDH1A1 (0.53) | ALDH1A1TACR1GAAMCHR1UBE2M | |
| SCHEMBL14221696 | 0.82 | USP2 (0.43) | ALDH1A1MCHR1SMN1; SMN2 | |
| SCHEMBL3033257 | 0.82 | ALDH1A1 (0.48) | ALDH1A1KDM4ETDP1HTTTACR1 | |
| SCHEMBL3038767 | 0.81 | MCHR1 (0.57) | ALDH1A1KDM4ETDP1TACR1GAA | |
| SCHEMBL3038611 | 0.81 | FAAH (0.49) | ALDH1A1KDM4ETDP1TACR1GAA | |
| SCHEMBL13222951 | 0.80 | ALDH1A1 (0.56) | ALDH1A1KDM4ETDP1HTTMCHR1 | |
| SCHEMBL13222899 | 0.79 | TACR1 (0.45) | ALDH1A1TACR1GAAMCHR1UBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | claimed |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | CCR2, CCR1, CCR5 | ALDH1A1 1247/4885KDM4E 3492/4885TDP1 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.